KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on SalesTimes Interest Earned

Novartis Ag (NVS) EBT Margin (2016 - 2024)

Novartis Ag's EBT Margin history spans 13 years, with the latest figure at 30.7% for Q2 2024.

  • On a quarterly basis, EBT Margin rose 997.0% to 30.7% in Q2 2024 year-over-year; TTM through Jun 2024 was 40.38%, a 1965.0% increase, with the full-year FY2025 number at 29.99%, up 288.0% from a year prior.
  • EBT Margin hit 30.7% in Q2 2024 for Novartis Ag, up from 23.36% in the prior quarter.
  • Over the last five years, EBT Margin for NVS hit a ceiling of 2028.51% in Q4 2020 and a floor of 14.17% in Q4 2021.
  • Historically, EBT Margin has averaged 342.5% across 5 years, with a median of 120.68% in 2020.
  • Biggest five-year swings in EBT Margin: plummeted -201434bps in 2021 and later soared 184055bps in 2022.
  • Tracing NVS's EBT Margin over 5 years: stood at 2028.51% in 2020, then plummeted by -99bps to 14.17% in 2021, then skyrocketed by 12989bps to 1854.72% in 2022, then tumbled by -99bps to 23.36% in 2023, then skyrocketed by 31bps to 30.7% in 2024.
  • Business Quant data shows EBT Margin for NVS at 30.7% in Q2 2024, 23.36% in Q4 2023, and 20.73% in Q2 2023.